By leveraging our pioneering expertise in the field of chemokine research, ChemoCentryx has generated a broad portfolio of medicines targeting the chemokine system, with six product candidates currently in pre-clinical and clinical stages of development. Our pipeline includes:Traficet-EN currently in Phase II clinical studies and initially being developed for inflammatory bowel disease. Traficet-EN targets a chemokine receptor called CCR9, which regulates the trafficking of inflammatory cells to the digestive tract. In a separate program, ChemoCentryx intends to take a new drug candidate for multiple sclerosis and cardiovascular disease, targeting the receptor CCR2, into clinical trials this year. Also, two promising compounds targeting novel chemokine receptors are in development for the treatment of cancers. Lastly, ChemoCentryx has two partnered programs. A CCR1 antagonist is being co-developed with Forest Laboratories for autoimmune disorders and CXCR3 receptor antagonists are being developed by ChemoCentryx's partner, Amgen-SF (formerly Tularik). Our pipeline of products targets the chemokine system, a network of ligands and receptors that act as the master control center for the immune system in inflammation and autoimmune disease. Each of our chemokine-based therapeutics act by correcting or modifying inappropriate immune system activities by binding to the precise chemokine receptor associated with the essential inflammatory processes underlying a given condition. The result:small molecule compounds designed to perform with high specificity and selectivity in order to minimize potential side effects and treat the root cause of disease. We continue to generate new products and to rapidly move them to clinical-stage development using our productive and proprietary drug discovery engine, known as EnabaLink. Our objective is to advance one product into the clinic every twelve to eighteen months. ChemoCentryx's product development strategy involves a two-pronged approach:ChemoCentryx focuses on the proprietary development of medicines in areas where the full value can be captured independently and leverages partnerships in select areas to capitalize on the commercial potential of a given therapeutic. The aim is always to maximize value by creating a balanced portfolio of independently developed and co-developed programs.
This article uses content from
http://www.AboutUs.org
